Journal
HEART FAILURE REVIEWS
Volume 21, Issue 1, Pages 95-102Publisher
SPRINGER
DOI: 10.1007/s10741-015-9522-7
Keywords
Adenosine; Adenosine A1 receptor; Partial agonist; Therapy; Heart failure; Mitochondria
Categories
Funding
- Bayer Healthcare AG
- Stealth Peptides, Inc.
- Amgen Corp.
- Johnson Johnson, Inc.
- Novartis Corp.
- Merck
- Takeda Pharmaceuticals
- National Institutes of Health
- European Union
- Health Resources Service Administration
- Alere
- Amgen
- Bayer
- Boehringer
- Cardio3Biosciences
- Celladon
- GSK
- Merck/MSD
- Novartis
- Servier
- Singulex
- Sphingotec
- Trevena
- Vifor
- ZS Pharma
- European Commission [FP7-242209-BIOSTAT-CHF]
- AstraZeneca
- German Ministry of Education and Research
Ask authors/readers for more resources
Heart failure (HF) represents a global public health and economic problem associated with unacceptable rates of death, hospitalization, and healthcare expenditure. Despite available therapy, HF carries a prognosis comparable to many forms of cancer with a 5-year survival rate of similar to 50 %. The current treatment paradigm for HF with reduced ejection fraction (EF) centers on blocking maladaptive neurohormonal activation and decreasing cardiac workload with therapies that concurrently lower blood pressure and heart rate. Continued development of hemodynamically active medications for stepwise addition to existing therapies carries the risk of limited tolerability and safety. Moreover, this treatment paradigm has thus far failed for HF with preserved EF. Accordingly, development of hemodynamically neutral HF therapies targeting primary cardiac pathologies must be considered. In this context, a partial adenosine A1 receptor (A1R) agonist holds promise as a potentially hemodynamically neutral therapy for HF that could simultaneous improve cardiomyocyte energetics, calcium homeostasis, cardiac structure and function, and long-term clinical outcomes when added to background therapies. In this review, we describe the physiology and pathophysiology of HF as it relates to adenosine agonism, examine the existing body of evidence and biologic rationale for modulation of adenosine A1R activity, and review the current state of drug development of a partial A1R agonist for the treatment of HF.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available